Abstract:Abstract Personalized oncology must overcome the complex challenge of distinct cancer phenotypes in each patient, formed in part in response to unique metabolic crosstalk among cells in the tumor microenvironment which can be a determining factor in therapeutic response. Although isotope tracing sheds light on differences of metabolite enrichments in tumor and normal tissues, quantifying the metabolic fluxes in patients remains elusive. The conventional metabolic flux analysis tools are unable to estimate patient metabolic fluxes because we are limited to a single time point enrichment datapoint from each patient’s in-vivo measurement at isotopic non-steady state. We overcame this challenge by generating training data from the limited patient data and implementing a machine learning model to predict fluxes. To generate training data, we first simulated constrained random fluxes and enrichment patterns at different time points using patient circulating metabolites enrichment via an isotopic non-stationary metabolic flux analysis framework. Using this data, we trained a convolutional neural network to predict flux ratios. To validate our model, we compared predicted flux ratios to the experimental data from mouse models for two different treatments. Our recent findings from a glioblastoma (GBM) mouse model study using conventional metabolic flux analysis revealed higher de novo guanosine monophosphate (GMP) synthesis in GBM than normal cortex. These tumors can be sensitive to mycophenolate mofetil (MMF) which inhibits inosine monophosphate dehydrogenase, but only if the major source of GMP production is de novo synthesis and not salvage. Our machine learning model can discriminate between sources of GMP synthesis in patients, thus enabling prediction of potential responders. Furthermore, we previously showed that serine uptake is higher in GBM than normal cortex, and a serine- and glycine-restricted diet slows tumor growth in mice. While both circulating serine and microenvironment-derived serine could account for serine uptake in GBM, we hypothesized that the circulating serine dependence would better predict response to dietary serine depletion. Hence, we combined patient scRNA-seq and metabolomics data to feed our neural network framework to estimate microenvironmental and circulating serine uptake in six patients with brain cancer. Thus, we have shown that our model can identify patients who will benefit from MMF treatment or a serine- and glycine-restricted diet, enabling administration of highly effective personalized treatments for GBM patients. Citation Format: Baharan Meghdadi, Anjali Mittal, Andrew J. Scott, Sravya Palavalasa, Daniel R. Wahl, Deepak Nagrath. Machine learning-based method to analyze metabolic fluxes of patient tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1789.

Abstract 3079: AMPK-HIF-1α signaling enhances glucose-derived de novo serine biosynthesis to promote glioblastoma growth

Abstract B050: Metabolic rewiring in human brain cancer

Abstract 427: A molecular signature for the G6PC3/SLC37A2/SLC37A4 interactors in glioblastoma disease progression and in the acquisition of a brain cancer stem cell phenotype

GDH1-catalytic glutaminolysis feedback activate EGFR/PI3K/AKT pathway and reprogram glioblastoma metabolism

Metabolic remodeling of pyrimidine synthesis pathway and serine synthesis pathway in human glioblastoma

Abstract 1666: Novel Glucose Transporter Inhibitors Decrease Glioblastoma Growth and Glucose Uptake

Abstract 2872: GLUT3 promotes metabolic plasticity that drives radiation resistance in glioblastoma

The mechanism of extracellular CypB promotes glioblastoma adaptation to glutamine deprivation microenvironment

EGFR Activates GDH1 Transcription to Promote Glutamine Metabolism Through MEK/ERK/ELK1 Pathway in Glioblastoma.

Purine Synthesis Promotes Maintenance of Brain Tumor Initiating Cells in Glioma

Abstract 4454: Manipulation of the amino acid metabolism promotes therapeutic efficacy through targeting lysosome in glioblastoma

Abstract 1789: Machine learning-based method to analyze metabolic fluxes of patient tumors

Abstract 25: SCAP Links Glucose to Lipids for Tumor Growth

HIF1α/ATF3 partake PGK1 K191/K192 succinylation by modulating P4HA1/succinate signaling in glioblastoma

Tmet-19. Rewiring Of Cortical Glucose Metabolism Fuels Human Brain Cancer Growth

Glucose regulates the HMGB1 signaling pathway through SIRT1 in glioma

MDB-74. SERINE/GLYCINE METABOLISM REPRESENTS A NOVEL TARGETABLE THERAPEUTIC VULNERABILITY IN MYC-AMPLIFIED MEDULLOBLASTOMA

Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma

Hexosaminidase B-driven cancer cell-macrophage co-dependency promotes glycolysis addiction and tumorigenesis in glioblastoma

Abstract 4422: Metabolic adaptations of glioblastoma in hypoxia is mediated by acox-1

Glucose metabolism in glioma: an emerging sight with ncRNAs